TM
IRWD icon

Torren Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Torren Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-72
Closed -$243 – 1209
2025
Q4 		$243 Buy
+72
New +$187 ﹤0.01% 1400

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Torren Management's IRWD Position: Q1 2026 in Review

Torren Management sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2026, closing a stake of 72 shares — an estimated $243 sold.

Torren Management first reported a position in IRWD in Q4 2025 and held it in 1 quarter. The position peaked at $243 in Q4 2025. 227 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Torren Management reported no remaining Ironwood Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Torren Management sold 72 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $243.
  • Torren Management first reported a position in Ironwood Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Torren Management's Ironwood Pharmaceuticals position peaked at $243 in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.